Vikas Lifecare

  • Market Cap: Micro Cap
  • Industry: Trading & Distributors
  • ISIN: INE161L01027
  • NSEID: VIKASLIFE
  • BSEID: 542655
INR
1.46
-0.03 (-2.01%)
BSENSE

Jun 25, 03:30 PM

BSE+NSE Vol: 36.12 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

36.12 lacs (49.72%) Volume

Shareholding (Mar 2026)

FII

0.26%

Held by 10 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

14.20%

Why is Vikas Lifecare Ltd falling/rising?

27-Jun-2026

As of 26-Jun, Vikas Lifecare Ltd's stock price is falling, currently at 1.46, reflecting a decline of 2.01%. The stock has underperformed the market significantly, with a year-to-date drop of 17.51% and ongoing financial challenges, including operating losses and weak debt servicing ability.

As of 26-Jun, Vikas Lifecare Ltd's stock price is falling, currently at 1.46, which reflects a change of -0.03 or -2.01%. The stock has underperformed the sector today by -0.33% and is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. <BR><BR>Over the past week, the stock has declined by 2.01%, while the benchmark Sensex has only decreased by 0.40%. This trend continues over a longer period, with the stock down 1.35% over the past month, compared to a 0.80% increase in the Sensex. Year-to-date, Vikas Lifecare has experienced a significant drop of 17.51%, while the Sensex has fallen by only 9.53%. The stock's performance over the past year is particularly concerning, with a decline of 43.19%, compared to a much smaller drop of 6.83% in the benchmark.<BR><BR>Despite a recent announcement of positive quarterly results in March 2026, which included a substantial growth in profit after tax and net sales, the company is still facing significant challenges. It has reported operating losses and a negative EBITDA of Rs. -48.34 crore, indicating weak long-term fundamental strength. The company's ability to service its debt is also weak, as evidenced by a poor EBIT to Interest ratio of -0.27 and a low return on equity of 2.54%. <BR><BR>These factors contribute to the stock's decline, as it has consistently underperformed the market and is considered risky compared to its historical valuations. Overall, the combination of negative financial indicators and poor stock performance relative to the market explains why Vikas Lifecare Ltd's stock price is falling.

View full answer

Should I buy, sell or hold Vikas Lifecare Ltd?

26-Jun-2026

Are Vikas Lifecare Ltd latest results good or bad?

25-Jun-2026

Vikas Lifecare Ltd's latest results show significant challenges, with a net profit of ₹41.57 crores overshadowed by an operating loss of ₹26.28 crores and a negative cash flow of ₹222 crores, indicating ongoing struggles despite a 73.78% increase in net sales. Overall, the financial health of the company remains concerning.

The latest results for Vikas Lifecare Ltd present a mixed picture, but overall, they indicate significant challenges. In Q4 FY26, the company reported a consolidated net profit of ₹41.57 crores, which might seem positive at first glance. However, this figure is misleading due to a substantial operating loss of ₹26.28 crores, resulting in an operating margin of -15.59%. This marks the lowest operating margin in seven quarters, highlighting severe operational difficulties.<BR><BR>While net sales surged by 73.78% quarter-on-quarter to ₹168.62 crores, this growth did not translate into profitability. The company continues to struggle with negative cash flows and a return on equity of -0.66%, indicating that it is destroying shareholder value rather than creating it. Furthermore, the year-on-year comparison reveals a staggering decline of 1533.45% in net profit compared to Q4 FY25.<BR><BR>The operational challenges are compounded by a negative cash flow from operations of ₹222 crores in FY25, raising concerns about the company's ability to sustain its business model. The volatility in revenues and persistent losses suggest that Vikas Lifecare is facing significant hurdles that could hinder any potential recovery.<BR><BR>In summary, while there are signs of revenue growth, the underlying financial health of Vikas Lifecare Ltd is concerning, leading to the conclusion that the latest results are more indicative of ongoing struggles rather than a turnaround.

View full answer

What does Vikas Lifecare do?

11-Jun-2026

Vikas Lifecare Ltd specializes in recycling plastic waste and manufacturing polymer compounds, operating as a Micro Cap company. As of December 2025, it reported net sales of 97 Cr and a net loss of 29 Cr.

Overview: <BR>Vikas Lifecare Ltd operates in the recycling of plastic waste and the trading and manufacturing of polymer compounds, positioned within the Trading & Distributors industry and categorized as a Micro Cap company.<BR><BR>History: <BR>Vikas Lifecare Limited was originally incorporated as Vikas Multicorp Limited in 1995. The company underwent a name change to Vikas Lifecare Limited, which was formalized with a Special Resolution and a fresh Certificate of Incorporation issued on April 09, 2021. The latest quarterly results reported net sales and profit for December 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 97 Cr (Quarterly Results - Dec 2025) <BR>Net Profit: -29 Cr (Quarterly Results - Dec 2025) <BR>Market Cap: INR 279 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 14 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: -0.66% <BR>Price to Book: 0.50<BR><BR>Contact Details: <BR>Address: G 1 34/1 East Punjabi Bagh, Vikas Apartments, New Delhi, Delhi: 110026 <BR>Tel: 91-011-40450110 <BR>Email: info@vikasmulticorp.com <BR>Website: http://www.vikaslifecarelimited.com

View full answer

How big is Vikas Lifecare?

11-Jun-2026

As of 10th June, Vikas Lifecare Ltd has a market capitalization of 279.00 Cr and reported Net Sales of 465.94 Cr, with a Net Profit loss of 26.06 Cr over the latest 4 quarters. Shareholder's Funds were 531.76 Cr and Total Assets were 724.76 Cr as of March 2025.

As of 10th June, Vikas Lifecare Ltd has a market capitalization of 279.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Vikas Lifecare reported Net Sales of 465.94 Cr. However, the company experienced a loss of 26.06 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 531.76 Cr and Total Assets were reported at 724.76 Cr.

View full answer

Who are in the management team of Vikas Lifecare?

11-Jun-2026

The management team of Vikas Lifecare includes Arvind Gupta (CFO), Anil Kumar, Ruby Bansal, Parul Rai (Company Secretary), Vijay Kumar Sharma (CEO), Sundeep Kumar Dhawan (Managing Director), Richa Sharma, and Chandan Kumar (Director & CFO), who oversee the company's operations and strategy.

The management team of Vikas Lifecare includes the following individuals:<BR><BR>1. **Arvind Gupta** - Director (Finance) & CFO<BR>2. **Anil Kumar** - Independent Director<BR>3. **Ruby Bansal** - Independent Director<BR>4. **Parul Rai** - Company Secretary & Compliance Officer<BR>5. **Vijay Kumar Sharma** - Director & Chief Executive Officer<BR>6. **Sundeep Kumar Dhawan** - Managing Director<BR>7. **Richa Sharma** - Independent Director<BR>8. **Chandan Kumar** - Director & CFO<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

View full answer

Who are the peers of the Vikas Lifecare?

11-Jun-2026

Vikas Lifecare's peers include Astal Lab, Agribio Spirits, Sakuma Exports, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus. In terms of management risk, growth, and capital structure, Vikas Lifecare ranks below average compared to its peers, with a 1-year return of -45.32%.

Peers: The peers of Vikas Lifecare are Astal Lab, Agribio Spirits, Sakuma Exports, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astal Lab and Chandrima Mercan, while Average management risk is found at Sicagen India, Sakuma Exports, Northern Spirits, and Stratmont Indus, and the rest. Below Average management risk is noted for Agribio Spirits, Vikas Lifecare, and Chandrima Mercan. In terms of growth, Excellent growth is seen at Astal Lab and Chandrima Mercan, while Average growth is found at Sicagen India, and the rest. Below Average growth is observed at Agribio Spirits, Sakuma Exports, and Vikas Lifecare. For capital structure, Excellent capital structure is noted at Chandrima Mercan, Good capital structure is found at Astal Lab, Agribio Spirits, Sakuma Exports, and Sicagen India, while Vikas Lifecare and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chandrima Mercan at 100.52%, while the lowest is Sakuma Exports at -46.46%. Vikas Lifecare's own 1-year return is -45.32%, which is slightly better than Sakuma Exports. Additionally, Agribio Spirits, Sakuma Exports, Vikas Lifecare, Sicagen India, Chandrima Mercan, Northern Spirits, and Stratmont Indus all have negative six-month returns.

View full answer

When is the next results date for Vikas Lifecare Ltd?

01-Feb-2026

The next results date for Vikas Lifecare Ltd is February 7, 2026.

The next results date for Vikas Lifecare Ltd is scheduled for February 7, 2026.

View full answer

How has been the historical performance of Vikas Lifecare?

15-Nov-2025

Vikas Lifecare has experienced fluctuating financial performance, with net sales increasing to 480.02 Cr in March 2025, but profitability declining significantly, resulting in a net loss of -10.61 Cr. Despite growth in total assets, cash flow from operations has worsened, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vikas Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vikas Lifecare's net sales have generally increased, reaching 480.02 Cr in March 2025 from 445.75 Cr in March 2024, although it slightly decreased from 476.05 Cr in March 2023. The total operating income followed a similar trend, peaking at 480.02 Cr in March 2025. However, the total expenditure has also risen, amounting to 501.62 Cr in March 2025, which has led to an operating profit (PBDIT) of 4.36 Cr, a decline from 30.49 Cr in the previous year. The company reported a profit before tax of -6.95 Cr in March 2025, down from 17.58 Cr in March 2024, resulting in a profit after tax of -5.00 Cr. The consolidated net profit also fell to -10.61 Cr in March 2025 from 14.03 Cr in March 2024. The total assets of Vikas Lifecare increased to 724.76 Cr in March 2025, up from 554.70 Cr in March 2024, while total liabilities rose to 724.76 Cr from 554.70 Cr in the same period. Cash flow from operating activities showed a negative trend, with -222.00 Cr in March 2025 compared to -41.00 Cr in March 2024, indicating challenges in cash generation. Overall, while Vikas Lifecare has seen growth in sales and assets, profitability has been inconsistent, reflecting a complex financial landscape.

View full answer

Is Vikas Lifecare overvalued or undervalued?

09-Jun-2025

As of July 22, 2024, Vikas Lifecare is considered overvalued and risky, with a negative PE ratio of -46.72 and an EV to EBITDA of -25.23, significantly underperforming against the Sensex with a year-to-date return of -38.77%.

As of 22 July 2024, the valuation grade for Vikas Lifecare has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE ratio of -46.72, an EV to EBITDA of -25.23, and a Price to Book Value of 0.89, which highlight the underlying financial challenges the company faces.<BR><BR>In comparison to its peers, Vikas Lifecare's valuation metrics are concerning, particularly when contrasted with industry standards. For instance, its PE ratio is significantly negative, while the EV to EBITDA ratio also reflects a troubling trend. Notably, the company has underperformed against the Sensex, with a year-to-date return of -38.77% compared to the Sensex's positive 5.56%. This performance further reinforces the notion that Vikas Lifecare is currently overvalued in the market.

View full answer

What is the technical trend for Vikas Lifecare?

09-Jun-2025

As of June 4, 2025, Vikas Lifecare's technical trend is bearish, supported by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, indicating a prevailing bearish market sentiment.

As of 4 June 2025, the technical trend for Vikas Lifecare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and Bollinger Bands both signaling bearish trends. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD and KST both being bearish. The Dow Theory indicates a mildly bearish trend on the weekly timeframe, while the monthly shows no trend. Overall, the indicators suggest a prevailing bearish sentiment in the market for Vikas Lifecare.

View full answer

Who are the top shareholders of the Vikas Lifecare?

06-Jun-2025

The top shareholders of Vikas Lifecare include promoter Vikas Garg with 13.1%, public shareholder Sylph Technologies at 3.1%, and individual investors holding 73.79%. There are also 18 Foreign Institutional Investors with a combined 0.46% stake, and no mutual funds currently hold shares.

The top shareholders of Vikas Lifecare include Vikas Garg, who is the promoter with the highest holding at 13.1%. The highest public shareholder is Sylph Technologies, holding 3.1%. Additionally, individual investors collectively hold a significant portion of the shares at 73.79%. The company also has 18 Foreign Institutional Investors (FIIs) with a combined holding of 0.46%. Notably, there are no mutual funds currently holding shares in the company.

View full answer

Has Vikas Lifecare declared dividend?

06-Jun-2025

No Dividend History Available

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.27
  • The company has been able to generate a Return on Equity (avg) of 2.54% signifying low profitability per unit of shareholders funds
2

Risky - Negative EBITDA

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Trading & Distributors

stock-summary
Market cap

INR 277 Cr (Micro Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

15

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

-0.66%

stock-summary
Price to Book

0.50

Revenue and Profits:
Net Sales:
169 Cr
(Quarterly Results - Mar 2026)
Net Profit:
42 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.74%
0%
17.74%
6 Months
-20.65%
0%
-20.65%
1 Year
-43.19%
0%
-43.19%
2 Years
-72.71%
0%
-72.71%
3 Years
-53.05%
0%
-53.05%
4 Years
-74.61%
0%
-74.61%
5 Years
-53.65%
0%
-53.65%

Vikas Lifecare for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015

24-Jun-2026 | Source : BSE

Disclosure under Regulation 30 of the SEBI (LODR) Regulations 2015

Board Meeting Outcome for Outcome Of Board Meeting Held On 24Th June 2026

24-Jun-2026 | Source : BSE

Outcome of Board Meeting held on 24th June 2026

Outcome Of Board Meeting Held On 24Th June 2026

24-Jun-2026 | Source : BSE

Outcome of Board Meeting held on 24th June 2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Vikas Lifecare Ltd has announced 4:21 rights issue, ex-date: 29 Oct 21

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.50%
EBIT Growth (5y)
-311.64%
EBIT to Interest (avg)
-2.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.19
Sales to Capital Employed (avg)
1.00
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0.03%
Institutional Holding
0.26%
ROCE (avg)
-1.14%
ROE (avg)
1.91%

Valuation key factors

Factor
Value
P/E Ratio
15
Industry P/E
15
Price to Book Value
0.49
EV to EBIT
-6.92
EV to EBITDA
-7.77
EV to Capital Employed
0.57
EV to Sales
0.75
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
-8.27%
ROE (Latest)
3.34%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

0.0258

Mutual Funds

Held by 0 Schemes

FIIs

Held by 10 FIIs (0.26%)

Promoter with highest holding

Vikas Garg (13.1%)

Highest Public shareholder

Srestha Finvest Limited (1.97%)

Individual Investors Holdings

79.34%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 73.78% vs -31.35% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 242.31% vs 75.44% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.62",
          "val2": "97.03",
          "chgp": "73.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.28",
          "val2": "-15.65",
          "chgp": "-67.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.55",
          "val2": "1.97",
          "chgp": "-21.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "41.57",
          "val2": "-29.21",
          "chgp": "242.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.59%",
          "val2": "-16.13%",
          "chgp": "0.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 2.97% vs 5.60% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 763.74% vs -104.71% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "233.71",
          "val2": "226.97",
          "chgp": "2.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.40",
          "val2": "0.11",
          "chgp": "-5,918.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.99",
          "val2": "1.69",
          "chgp": "76.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.04",
          "val2": "-0.91",
          "chgp": "763.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.74%",
          "val2": "0.05%",
          "chgp": "-2.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -4.08% vs 9.74% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -200.13% vs -148.77% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "330.74",
          "val2": "344.82",
          "chgp": "-4.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.05",
          "val2": "-2.02",
          "chgp": "-991.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.96",
          "val2": "3.11",
          "chgp": "59.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.17",
          "val2": "-7.72",
          "chgp": "-200.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6.67%",
          "val2": "-0.59%",
          "chgp": "-6.08%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 4.03% vs 7.69% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 273.52% vs -175.62% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "499.36",
          "val2": "480.02",
          "chgp": "4.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.34",
          "val2": "-21.60",
          "chgp": "-123.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.52",
          "val2": "4.57",
          "chgp": "42.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "18.41",
          "val2": "-10.61",
          "chgp": "273.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9.68%",
          "val2": "-4.50%",
          "chgp": "-5.18%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
168.62
97.03
73.78%
Operating Profit (PBDIT) excl Other Income
-26.28
-15.65
-67.92%
Interest
1.55
1.97
-21.32%
Exceptional Items
0.00
0.00
Consolidate Net Profit
41.57
-29.21
242.31%
Operating Profit Margin (Excl OI)
-15.59%
-16.13%
0.54%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 73.78% vs -31.35% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 242.31% vs 75.44% in Dec 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
233.71
226.97
2.97%
Operating Profit (PBDIT) excl Other Income
-6.40
0.11
-5,918.18%
Interest
2.99
1.69
76.92%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.04
-0.91
763.74%
Operating Profit Margin (Excl OI)
-2.74%
0.05%
-2.79%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 2.97% vs 5.60% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 763.74% vs -104.71% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
330.74
344.82
-4.08%
Operating Profit (PBDIT) excl Other Income
-22.05
-2.02
-991.58%
Interest
4.96
3.11
59.49%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.17
-7.72
-200.13%
Operating Profit Margin (Excl OI)
-6.67%
-0.59%
-6.08%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -4.08% vs 9.74% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is -200.13% vs -148.77% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
499.36
480.02
4.03%
Operating Profit (PBDIT) excl Other Income
-48.34
-21.60
-123.80%
Interest
6.52
4.57
42.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.41
-10.61
273.52%
Operating Profit Margin (Excl OI)
-9.68%
-4.50%
-5.18%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 4.03% vs 7.69% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 273.52% vs -175.62% in Mar 2025

stock-summaryCompany CV
About Vikas Lifecare Ltd stock-summary
stock-summary
Vikas Lifecare Ltd
Micro Cap
Trading & Distributors
Vikas Lifecare Limited was originally incorporated as Vikas Multicorp Limited in 1995. The Company changed the name from 'Vikas Multicorp Limited' to 'Vikas Lifecare Limited' by passing a Special Resolution upon change of name and fresh Certificate of incorporation issued by the Registrar of Companies, NCT Delhi on April 09, 2021. The Company operates in the business of recycling plastic waste and trading of polymer compounds, manufacturing of polymers compounds.
Company Coordinates stock-summary
Company Details
G 1 34/1 East Punjabi Bagh, vikas Apartments New Delhi Delhi : 110026
stock-summary
Tel: 91-011-40450110
stock-summary
info@vikasmulticorp.com
Registrar Details